Literature DB >> 31843789

Tenofovir may be superior to entecavir for preventing hepatocellular carcinoma and mortality in individuals chronically infected with HBV: a meta-analysis.

Yu-Xian Teng1, Min-Jun Li1, Bang-De Xiang1, Jian-Hong Zhong2.   

Abstract

Entities:  

Keywords:  hepatitis B; hepatobiliary cancer

Mesh：

Substances：

Year:  2019        PMID： 31843789     DOI： 10.1136/gutjnl-2019-320326

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  3 in total

Review 1.  Systematic Review with Meta-Analysis: Comparison of the Risk of Hepatocellular Carcinoma in Antiviral-Naive Chronic Hepatitis B Patients Treated with Entecavir versus Tenofovir: The Devil in the Detail.

Authors:  Hyunwoo Oh; Hyo Young Lee; Jihye Kim; Yoon Jun Kim
Journal:  Cancers (Basel)       Date:  2022-05-25       Impact factor: 6.575

2.  No difference in hepatocellular carcinoma risk in chronic hepatitis B patients treated with tenofovir vs entecavir: evidence from an updated meta-analysis.

Authors:  Jie Yuan; Yang Peng; Fa-Bao Hao; Ya-Qin Wang; Chun-Rui Wang; Guo-Chao Zhong
Journal:  Aging (Albany NY)       Date:  2021-02-26       Impact factor: 5.682

3.  Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis.

Authors:  Ze-Hong Huang; Gui-Yang Lu; Ling-Xian Qiu; Guo-Hua Zhong; Yue Huang; Xing-Mei Yao; Xiao-Hui Liu; Shou-Jie Huang; Ting Wu; Quan Yuan; Ying-Bin Wang; Ying-Ying Su; Jun Zhang; Ning-Shao Xia
Journal:  BMC Cancer       Date:  2022-03-17       Impact factor: 4.430
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.